Central Nervous System Tumors of Uncertain Differentiation

Overview

Journal World Neurosurg X

Date 2024 Mar 8

PMID 38455248

Authors

Javier A Jacobo

Affiliations

Soon will be listed here.

Abstract

Background: The 2021 World Health Organization classification for brain tumors introduced several new entities and categories.Tumors of uncertain differentiation are a new subcategory that includes the intracranial mesenchymal tumor, FET-CREB fusion-positive; the CIC-rearranged sarcoma; and the Primary intracranial sarcoma, DICER1-mutant.

Methods: A search was made in Pubmed and Google Scholar to include all articles with the term "uncertain differentiation", "Mesenchymal, non-meningothelial", "FET-CREB fusion positive", "DICER1-mutant sarcoma" and "CIC-Rearranged sarcoma" in their title. These articles were reviewed to draft a concise review on this subject.

Results: This review on CNS non-meningothelial mesenchymal tumors is meant to provide an update with diagnostic, prognostic, and therapeutic implications.

Conclusion: Tumors of uncertain differentiation include a variety of mesenchymal, non-meningothelial tumors that have distinct molecular characteristics and consequently behave in a very particular matter.Given that these tumors have been described only recently, there is still an important lack of information regarding the most appropriate treatment and prognosis.

References

Liu K, Shang H, Cacciotti C, Everdell E, Aizer A, Rahman R . DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis. J Neurooncol. 2022; 157(3):499-510. DOI: 10.1007/s11060-022-03994-w. View

Sloan E, Gupta R, Koelsche C, Chiang J, Villanueva-Meyer J, Alexandrescu S . Intracranial mesenchymal tumors with FET-CREB fusion are composed of at least two epigenetic subgroups distinct from meningioma and extracranial sarcomas. Brain Pathol. 2021; 32(4):e13037. PMC: 9245938. DOI: 10.1111/bpa.13037. View

Diaz Coronado R, Mynarek M, Koelsche C, Mora Alferez P, Zambrano S, Wachtel Aptowitzer A . Primary central nervous system sarcoma with DICER1 mutation-treatment results of a novel molecular entity in pediatric Peruvian patients. Cancer. 2021; 128(4):697-707. DOI: 10.1002/cncr.33977. View

Yoshida A, Goto K, Kodaira M, Kobayashi E, Kawamoto H, Mori T . CIC-rearranged Sarcomas: A Study of 20 Cases and Comparisons With Ewing Sarcomas. Am J Surg Pathol. 2015; 40(3):313-23. DOI: 10.1097/PAS.0000000000000570. View

Konstantinidis A, Cheesman E, OSullivan J, Pavaine J, Avula S, Pizer B . Intracranial Angiomatoid Fibrous Histiocytoma with EWSR1-CREB Family Fusions: A Report of 2 Pediatric Cases. World Neurosurg. 2019; 126:113-119. DOI: 10.1016/j.wneu.2019.02.107. View

Lopez-Nunez O, Cafferata B, Santi M, Ranganathan S, Pearce T, Kulich S . The spectrum of rare central nervous system (CNS) tumors with EWSR1-non-ETS fusions: experience from three pediatric institutions with review of the literature. Brain Pathol. 2020; 31(1):70-83. PMC: 8018079. DOI: 10.1111/bpa.12900. View

Le Loarer F, Pissaloux D, Watson S, Godfraind C, Galmiche-Rolland L, Silva K . Clinicopathologic Features of CIC-NUTM1 Sarcomas, a New Molecular Variant of the Family of CIC-Fused Sarcomas. Am J Surg Pathol. 2018; 43(2):268-276. DOI: 10.1097/PAS.0000000000001187. View

Sakaguchi M, Nakano Y, Honda-Kitahara M, Kinoshita M, Tanaka S, Oishi M . Two cases of primary supratentorial intracranial rhabdomyosarcoma with DICER1 mutation which may belong to a "spindle cell sarcoma with rhabdomyosarcoma-like feature, DICER1 mutant". Brain Tumor Pathol. 2019; 36(4):174-182. DOI: 10.1007/s10014-019-00352-z. View

Tauziede-Espariat A, Sievers P, Larousserie F, Benzakoun J, Guillemot D, Pierron G . An integrative histopathological and epigenetic characterization of primary intracranial mesenchymal tumors, FET:CREB-fused broadening the spectrum of tumor entities in comparison with their soft tissue counterparts. Brain Pathol. 2021; 32(1):e13010. PMC: 8713527. DOI: 10.1111/bpa.13010. View

10.

Koelsche C, Mynarek M, Schrimpf D, Bertero L, Serrano J, Sahm F . Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. Acta Neuropathol. 2018; 136(2):327-337. DOI: 10.1007/s00401-018-1871-6. View

11.

Ito M, Ishikawa M, Kitajima M, Narita J, Hattori S, Endo O . A case report of CIC-rearranged undifferentiated small round cell sarcoma in the cerebrum. Diagn Cytopathol. 2016; 44(10):828-32. DOI: 10.1002/dc.23520. View

12.

Kawamura-Saito M, Yamazaki Y, Kaneko K, Kawaguchi N, Kanda H, Mukai H . Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation. Hum Mol Genet. 2006; 15(13):2125-37. DOI: 10.1093/hmg/ddl136. View

13.

Tauziede-Espariat A, Hasty L, Metais A, Varlet P . Mesenchymal non-meningothelial tumors of the central nervous system: a literature review and diagnostic update of novelties and emerging entities. Acta Neuropathol Commun. 2023; 11(1):22. PMC: 9896826. DOI: 10.1186/s40478-023-01522-z. View

14.

Ballester L, Meis J, Lazar A, Prabhu S, Hoang K, Leeds N . Intracranial Myxoid Mesenchymal Tumor With EWSR1-ATF1 Fusion. J Neuropathol Exp Neurol. 2020; 79(3):347-351. DOI: 10.1093/jnen/nlz140. View

15.

Kamihara J, Paulson V, Breen M, Laetsch T, Rakheja D, Shulman D . DICER1-associated central nervous system sarcoma in children: comprehensive clinicopathologic and genetic analysis of a newly described rare tumor. Mod Pathol. 2020; 33(10):1910-1921. DOI: 10.1038/s41379-020-0516-1. View

16.

Schweizer L, Hartmann W, Koch A, Nunninger M, Thomale U, Pennacchietti V . Evidence of neural crest cell origin of a DICER1 mutant CNS sarcoma in a child with DICER1 syndrome and NRAS-mutant neurocutaneous melanosis. Neuropathol Appl Neurobiol. 2022; 48(6):e12830. DOI: 10.1111/nan.12830. View

17.

Sugita S, Arai Y, Aoyama T, Asanuma H, Mukai W, Hama N . NUTM2A-CIC fusion small round cell sarcoma: a genetically distinct variant of CIC-rearranged sarcoma. Hum Pathol. 2017; 65:225-230. DOI: 10.1016/j.humpath.2017.01.012. View

18.

Connolly E, Bhadri V, Wake J, Ingley K, Lewin J, Bae S . Systemic treatments and outcomes in CIC-rearranged Sarcoma: A national multi-centre clinicopathological series and literature review. Cancer Med. 2022; 11(8):1805-1816. PMC: 9041083. DOI: 10.1002/cam4.4580. View

19.

Meredith D, Alexandrescu S . Embryonal and non-meningothelial mesenchymal tumors of the central nervous system - Advances in diagnosis and prognostication. Brain Pathol. 2022; 32(4):e13059. PMC: 9245947. DOI: 10.1111/bpa.13059. View

20.

Louis D, Perry A, Wesseling P, Brat D, Cree I, Figarella-Branger D . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8):1231-1251. PMC: 8328013. DOI: 10.1093/neuonc/noab106. View